#Coronavirus Disease Research #References (AMEDEO, Oct. 24 '26)

 

Emerg Infect Dis

1. IKEBE T, Otsuka H, Sasaki M, Yamaguchi T, et al
   Post-COVID-19 Expansion of Streptococcus pyogenes Lineages Causing Toxic Shock Syndrome, Japan, 2023-2024.
   Emerg Infect Dis. 2026;32:1902-1906.
   PubMed         Abstract available
   
   
2. KYDYRMANOV A, Kassymbekov Y, Nuralibekov S, Sabyrzhan T, et al
   Middle East Respiratory Syndrome Coronavirus in Camels, Kazakhstan, 2025.
   Emerg Infect Dis. 2026;32:1907-1912.
   PubMed         Abstract available
   
   
3. TE MARVELDE MR, Mykytyn AZ, Raadsen MP, Bouffier AHJ, et al
   Serologic Testing for Middle East Respiratory Syndrome Coronavirus and SARS-CoV-2 Cross-Reactive Immune Responses, the Netherlands.
   Emerg Infect Dis. 2026;32:1874-1878.
   PubMed         Abstract available
   
   
4. HSIEH YC, Lin CC, Wu JW, Liu YH, et al
   Emergence of Novel Macrolide-Resistant Mycoplasma pneumoniae Sequence Type 3 Subclades in Children after COVID-19 Pandemic, Taiwan.
   Emerg Infect Dis. 2026;32:1827-1837.
   PubMed         Abstract available
   
   
5. OTIENO JR, Albarraq AM, Selvaraj FA, Al Mehairi AO, et al
   Global Genomic Surveillance of Middle East Respiratory Syndrome Coronavirus.
   Emerg Infect Dis. 2026;32:1816-1826.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

6. LIU X, Hua Q, Dai R, Ma L, et al
   Humoral immune responses following inactivated COVID-19 vaccine with different booster intervals: a randomized interventional immunogenicity study.
   Int J Infect Dis. 2026 Oct 19:109196. doi: 10.1016/j.ijid.2026.109196.
   PubMed         Abstract available
   
   
7. M TK, Karina AL, Alejandro DB, Maria de la Luz MO, et al
   Randomized controlled trial of pirfenidone XR for patients with COVID-19 and exploration of effects on long-COVID incidence.
   Int J Infect Dis. 2026 Oct 19:109186. doi: 10.1016/j.ijid.2026.109186.
   PubMed         Abstract available
   
   
8. JANHA RE, Bah A, Sonko B, Mohammed NI, et al
   SARS-CoV-2 Seroprevalence and Antibody Dynamics in The Gambia During the Transition from Pandemic to Endemic Circulation - 2022 and 2023.
   Int J Infect Dis. 2026 Oct 21:109194. doi: 10.1016/j.ijid.2026.109194.
   PubMed         Abstract available
   
   

   
   J Med Virol

9. M R K, Das S, Jain C, Dewan P, et al
   Respiratory Viral Infections in Febrile Children With Lymphoreticular Malignancies: A Single-Centre Descriptive Study.
   J Med Virol. 2026;98:e71180.
   PubMed         Abstract available
   
   
10. LEE SS, Chan DP, Wong BC, Cheung DKF, et al
    Resurgence of Sexually Transmitted Hepatitis C Virus Infection in Men Who Have Sex With Men Living With HIV.
    J Med Virol. 2026;98:e71185.
    PubMed         Abstract available
    
    

    
    J Travel Med

11. ALSHAHRANI NZ, Albeshry AM, Awan Z, Rashid H, et al
    Prevalence of respiratory viruses among pilgrims in Saudi Arabia during the Hajj 2026: a cross-sectional study.
    J Travel Med. 2026 Oct 19:taag093. doi: 10.1093.
    PubMed         Abstract available
    
    
12. ALSHAHRANI AM, Okmi EA, Mohammed M, Abdalla O, et al
    Epidemiology of MERS-CoV in Saudi Arabia, 2012-2025: a nationwide surveillance analysis.
    J Travel Med. 2026 Oct 20:taag094. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Virol

13. ULUSAN S, Markmann AJ, Vanna UP, Castillo I, et al
    Pooled intravenous immunoglobulins exhibit broad binding and Fc-mediated activity against diverse SARS-CoV-2 variants.
    J Virol. 2026 Oct 22:e0147126. doi: 10.1128/jvi.01471.
    PubMed         Abstract available
    
    

    
    JAMA

14. LEUNG PB, Davis AM, Marks KM
    Clinical Practice Guidelines on Antiviral Therapies for Adults With COVID-19 Infection-Reply.
    JAMA. 2026 Oct 22. doi: 10.1001/jama.2026.17751.
    PubMed        
    
    
15. TSENG CH, Liu PY, Yeh TK
    Clinical Practice Guidelines on Antiviral Therapies for Adults With COVID-19 Infection.
    JAMA. 2026 Oct 22. doi: 10.1001/jama.2026.17748.
    PubMed        
    
    
16. PUECHAL X, Pugnet G, Thoreau B, de Moreuil C, et al
    Rituximab vs Azathioprine for Eosinophilic Granulomatosis With Polyangiitis Maintenance Therapy: A Randomized Clinical Trial.
    JAMA. 2026 Oct 22. doi: 10.1001/jama.2026.15278.
    PubMed         Abstract available
    
    

    
    Science

17. KUPFERSCHMIDT K
    Vaccine trial is a ray of hope in Congo's Ebola epidemic.
    Science. 2026;394:364-365.
    PubMed         Abstract available
    

#Coronavirus Disease Research #References (AMEDEO, Oct. 10 '26)

 

Ann Intern Med

1. REIS G, Dos Santos Moreira Silva EA, Medeiros Silva DC, Thabane L, et al
   Effect of Fluvoxamine and Metformin for Fatigue in Patients With Long COVID : An Adaptive Randomized Trial.
   Ann Intern Med. 2026 Oct 6. doi: 10.7326/ANNALS-26-02144.
   PubMed         Abstract available
   
   

   
   Br J Anaesth

2. SHRIMPTON AJ, Brown JM, Cook TM, Bzdek BR, et al
   The last breath of the aerosol-generating procedure? Implications for anaesthesia of Scotland's new infection control guidance.
   Br J Anaesth. 2026 Oct 3:S0007-0912(26)00702-6. doi: 10.1016/j.bja.2026.
   PubMed         Abstract available
   
   

   
   Infect Control Hosp Epidemiol

3. GRIFFIN M, Ikenberry H, Gauger J, Kuehnel N, et al
   Association between air sampling for viral respiratory pathogens and acute respiratory tract infection cases in the emergency department.
   Infect Control Hosp Epidemiol. 2026 Oct 7:1-3. doi: 10.1017/ice.2026.10538.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

4. DAVIDO B, Loubet P
   Beyond Oxygen Requirement: Rethinking Patient Selection for Oral Antiviral Therapy to Inform Trial Design in the Omicron Era.
   Int J Infect Dis. 2026 Oct 6:109171. doi: 10.1016/j.ijid.2026.109171.
   PubMed         Abstract available
   
   

   
   J Med Virol

5. ZARLENGA B, Wallet F, Gaymard A, Lukaszewicz AC, et al
   Pulmonary Herpes Simplex Virus Reactivation in Invasively Mechanically Ventilated Patients With COVID-19 in Intensive Care Unit.
   J Med Virol. 2026;98:e71170.
   PubMed         Abstract available
   
   

   
   J Virol

6. LIU Z, Zhang J, Ding Q, Yang C, et al
   Real-time tracking of dual-labeled fluorescent SARS-CoV-2 reveals that the nucleocapsid mutations R203K/G204R accelerate viral uncoating.
   J Virol. 2026 Oct 6:e0108626. doi: 10.1128/jvi.01086.
   PubMed         Abstract available
   
   
7. MA W, Jiang X, Li M
   Receptor-binding geometry constrains viral antigenic evolution through fitness-evasion coupling.
   J Virol. 2026 Oct 5:e0131626. doi: 10.1128/jvi.01316.
   PubMed         Abstract available
   
   
8. ZHANG Y, Duan Y, Shi L, Zhu X, et al
   A live PRV-vectored bivalent vaccine elicits dual protection against pseudorabies virus and swine acute diarrhea syndrome coronavirus.
   J Virol. 2026 Oct 5:e0119326. doi: 10.1128/jvi.01193.
   PubMed         Abstract available
   
   
9. LI A, Si H, Wu K, Zhang Q, et al
   Natural variation in BtSARSr-CoV nsp12 harbors adaptive mutations that enhance viral replication and spillover risk in humans.
   J Virol. 2026 Oct 5:e0134326. doi: 10.1128/jvi.01343.
   PubMed         Abstract available
   
   

   
   Nature

10. RATHKEY JK, Choi SS, van Unen V, Zhang H, et al
    Human lung organoid modelling of tissue-resident antiviral T cell responses.
    Nature. 2026 Oct 7. doi: 10.1038/s41586-026-11114.
    PubMed         Abstract available
    
    

    
    Science

11. HUUS KE, Abo H, Tan YH, Atay E, et al
    The human gut microbiome primes fever after vaccination.
    Science. 2026;394:eaea7733.
    PubMed         Abstract available

#Coronavirus Disease Research #References (AMEDEO, Oct. 3 '26)

 

Emerg Infect Dis

1. BHUIYA S, Shuvo TA, Hassan MZ, Aleem MA, et al
   The Impermanence of Public Health Gains-Lessons Learned from Measles Resurgence, Bangladesh, 2026.
   Emerg Infect Dis. 2026;32.
   PubMed         Abstract available
   
   
2. MADDEN EF, Ellis SL, Parisi A, Selvey CE, et al
   Age Differences in Pertussis Epidemics, New South Wales, Australia, 2015 and 2024.
   Emerg Infect Dis. 2026;32:1759-1762.
   PubMed         Abstract available
   
   

   
   Graefes Arch Clin Exp Ophthalmol

3. ZONTAG N, Wygnanski-Jaffe T, Bahir D, Ben-Zion I, et al
   Impact of COVID-19 on refractive amblyopia risk factors in 5-years-old children: A nationwide cross sectional study.
   Graefes Arch Clin Exp Ophthalmol. 2026 Sep 26. doi: 10.1007/s00417-026-07511.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

4. KAGUJJE M, Kerkhoff AD, Maimbolwa M, Sanjase N, et al
   Clinically diagnosed pulmonary TB and its association with mortality in Zambia: a secondary data analysis of a prospective diagnostic cohort.
   Int J Infect Dis. 2026 Sep 30:109141. doi: 10.1016/j.ijid.2026.109141.
   PubMed         Abstract available
   
   
5. GUDINA EK, Abera EG, Ali S, Maleko WA, et al
   Respiratory viral and bacterial pathogen dynamics among healthcare workers and community members in Ethiopia: A prospective cohort study.
   Int J Infect Dis. 2026 Sep 30:109157. doi: 10.1016/j.ijid.2026.109157.
   PubMed         Abstract available
   
   
6. EINARSDOTTIR S, Fei T, Sotelo-Alva MI, Gomez-Llobell M, et al
   Respiratory Viral Infections Following CAR-T Cell Therapy for Lymphoma and Myeloma: Severity and Immune Correlates.
   Int J Infect Dis. 2026 Sep 27:109138. doi: 10.1016/j.ijid.2026.109138.
   PubMed         Abstract available
   
   
7. NAKAJO K, Miyama T, Nagata M, Ko YK, et al
   Resurgence of measles in Japan, a highly vaccinated country: a risk assessment study.
   Int J Infect Dis. 2026 Sep 26:109143. doi: 10.1016/j.ijid.2026.109143.
   PubMed         Abstract available
   
   

   
   J Infect

8. NAZARETH J, Martin CA, Pan D, Barr IG, et al
   Ethnic differences in inactivated influenza vaccine immunogenicity in UK Healthcare Workers: A two-year prospective longitudinal study.
   J Infect. 2026 Sep 29:106862. doi: 10.1016/j.jinf.2026.106862.
   PubMed         Abstract available
   
   

   
   J Med Virol

9. FREITAS NL, Gomes YCP, Nogueira FCS, Echevarria-Lima J, et al
   Acute Neurological Manifestations in COVID-19 Are Associated With Complement Activation and Glia-Promoted Neuroinflammation.
   J Med Virol. 2026;98:e71165.
   PubMed         Abstract available
   
   

   
   J Virol

10. ALI MS, O'Brien A, Qing E, Sarkar L, et al
    A chimeric murine coronavirus with altered deISGylase and proteolytic activities exhibits attenuated viral pathogenesis.
    J Virol. 2026 Sep 30:e0085726. doi: 10.1128/jvi.00857.
    PubMed         Abstract available
    
    
11. ZHANG N, Xu Y, Chen Y, Ma M, et al
    DEAD-box RNA helicase 21 interacts with the nucleocapsid protein and inhibits porcine deltacoronavirus infection through upregulation of interferon responses.
    J Virol. 2026 Sep 30:e0116926. doi: 10.1128/jvi.01169.
    PubMed         Abstract available
    
    
12. SUN M, Yuan C, Duan Y, Shi L, et al
    GSK3 maintains NSP12 stability to promote bat-origin swine acute diarrhea syndrome coronavirus infection.
    J Virol. 2026 Sep 30:e0068326. doi: 10.1128/jvi.00683.
    PubMed         Abstract available
    
    
13. ZENG M, Liu D, Zhang J, Zhang L, et al
    MOV10 inhibits SADS-CoV replication by enhancing TRIM24-mediated K63-linked TRAF3 ubiquitination, and this inhibition is antagonized by viral N protein.
    J Virol. 2026 Sep 29:e0121526. doi: 10.1128/jvi.01215.
    PubMed         Abstract available
    
    

    
    Radiology

14. KIM N
    A 5-year Follow-up on the Persistence of Post-COVID-19 Lung Injury.
    Radiology. 2026;320:e262429.
    PubMed        
    

#Coronavirus Disease Research #References (AMEDEO, September 26 '26)

 

Clin Infect Dis

1. LEWIS NM, Cleary S, Harker EJ, Safdar B, et al
   Influenza vaccine effectiveness against influenza A-associated hospitalization and severe in-hospital outcomes among adults in the United States, 2024-2025.
   Clin Infect Dis. 2026 Sep 26:ciag540. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

2. MICHELE P, Serena M, Anna B, Alberto Z, et al
   Post-pandemic re-establishment of respiratory virus seasonality and molecular epidemiology of Rhinovirus/Enterovirus in Northern Italy: a three-year surveillance study (2023-2026).
   Int J Infect Dis. 2026 Sep 21:109132. doi: 10.1016/j.ijid.2026.109132.
   PubMed         Abstract available
   
   

   
   J Infect

3. RAO X, Fan H, Ding S, Zhang C, et al
   Meta-analysis of Maternal SARS-CoV-2 Infection and Child Growth and Development.
   J Infect. 2026 Sep 24:106869. doi: 10.1016/j.jinf.2026.106869.
   PubMed        
   
   

   
   J Med Virol

4. CHEN Y, Shang M, Dou S, Wang X, et al
   Changes in Dengue Epidemiology in China Before, During, and After COVID-19 2015-2024: A Retrospective National Surveillance and Spatiotemporal Study.
   J Med Virol. 2026;98:e71162.
   PubMed         Abstract available
   
   

   
   J Virol

5. PARK H-S, Matsuoka Y, Santos C, Duncan EF, et al
   Co-administration of intranasal parainfluenza virus vaccines expressing antigenically distinct SARS-CoV-2 S antigens elicits broad and durable immunity in hamsters.
   J Virol. 2026 Sep 24:e0093826. doi: 10.1128/jvi.00938.
   PubMed         Abstract available
   
   

   
   JAMA

6. ANDERER S
   FDA Approves Updated COVID-19 Vaccines for 2026-2027.
   JAMA. 2026 Sep 25. doi: 10.1001/jama.2026.14727.
   PubMed        
   
   

   
   Lancet

7. CALDERON-LARRANAGA S, Bakhti R, Etemadi M, Fakih L, et al
   The NUS-Lancet PRIME Commission: transforming pandemic readiness for equity.
   Lancet. 2026;408:1211-1274.
   PubMed        
   
   

   
   Radiology

8. HAN X, Guo Y, Fan W, Nie Z, et al
   Five-year Quantitative Chest CT and Hyperpolarized Xenon 129 Ventilation MRI Findings in Survivors of COVID-19 Pneumonia.
   Radiology. 2026;320:e261153.
   PubMed         Abstract available

#Coronavirus Disease Research #References (AMEDEO, September 19 '26)

 

Am J Obstet Gynecol

1. HABBOUS S, Surani A, Leyland NA, Murji A, et al
   Uptake and outcomes associated with outpatient hysterectomy in Ontario, Canada.
   Am J Obstet Gynecol. 2026 Sep 18:S0002-9378(26)00500.
   PubMed         Abstract available
   
   

   
   Antiviral Res

2. DU PONT V, Han D, Li J, Rodriguez L, et al
   Remdesivir maintains antiviral potency against clinically relevant SARS-CoV-2 Nsp12 substitutions.
   Antiviral Res. 2026;255:106533.
   PubMed         Abstract available
   
   
3. MARTINEZ-ARRIBAS B, Diaz-Gonzalez R, Weaver J, Walden M, et al
   Identification of 1,2-dihydroquinazolin-2-ones kinase inhibitors as anti-coronavirus agents.
   Antiviral Res. 2026 Sep 15:106534. doi: 10.1016/j.antiviral.2026.106534.
   PubMed         Abstract available
   
   
4. NAGAHAWATTA DP, Jeong SH, Liyanage NM, Jayawardena TU, et al
   Marine phlorotannins block SARS-CoV-2 entry via ACE2 and attenuate pulmonary inflammation in K18-hACE2 transgenic mice.
   Antiviral Res. 2026 Sep 15:106532. doi: 10.1016/j.antiviral.2026.106532.
   PubMed         Abstract available
   
   

   
   BMJ

5. WISE J
   Covid-19 inquiry: Additional psychological support for doctors would be rolled out in future pandemic, government says.
   BMJ. 2026;394:e100866.
   PubMed        
   
   
6. WILLMAN D
   US officials knew covid vaccine safety system was flawed-but turned aside the FDA doctor who alerted them.
   BMJ. 2026;394:e100806.
   PubMed        
   
   

   
   Emerg Infect Dis

7. DUTCHER HA, Antkiewicz DS, Roguet AJ, Shafer MM, et al
   Implementation and Early Outcomes of Laboratory Proficiency Testing Program for the National Wastewater Surveillance System, United States, 2024.
   Emerg Infect Dis. 2026;32:19-25.
   PubMed         Abstract available
   
   
8. BI K, Sandoval M, Nguyen T, Perez I, et al
   Temporal Alignment of Wastewater Signals with Clinical Indicators of Respiratory Illness Postpandemic, Texas, USA.
   Emerg Infect Dis. 2026;32:43-52.
   PubMed         Abstract available
   
   
9. MARK-CAREW M, Bias M, Reckling S, Madhobi K, et al
   Progress and Expansion of the National Wastewater Surveillance System, United States, 2020-2024.
   Emerg Infect Dis. 2026;32:3-13.
   PubMed         Abstract available
   
   
10. LEFFERTS B, Leary A, Bruden D, Blake I, et al
    Wastewater Respiratory Virus Surveillance in Remote Community, Alaska, USA, 2022-2024.
    Emerg Infect Dis. 2026;32:71-79.
    PubMed         Abstract available
    
    
11. MOORE JT, Rose-McCully K, Valencia D, Turner H, et al
    Exploration of Public Perceptions of Wastewater Surveillance, United States, June 2024.
    Emerg Infect Dis. 2026;32:115-118.
    PubMed         Abstract available
    
    

    
    Eur J Radiol

12. SCHMIDT K, Steinberger M, Woellert S, Klein M, et al
    CT radiation exposure of emergency department patients before, during and after the COVID-19 pandemic.
    Eur J Radiol. 2026;205:113211.
    PubMed         Abstract available
    
    

    
    Int J Infect Dis

13. HERRERO RL, Jimenez PM, Del Olmo DO, Prieto-Utrera RD, et al
    Epidemiological trends in sepsis in Spain: incidence, in-hospital mortality, and healthcare burden (2017-2022).
    Int J Infect Dis. 2026 Sep 16:109121. doi: 10.1016/j.ijid.2026.109121.
    PubMed         Abstract available
    
    
14. XU M, Huang Y, Ma H, Wu Z, et al
    A Multi-model Counterfactual Analysis of Human Brucellosis in China: Spatiotemporal Epidemiology and Heterogeneous Pandemic-associated Deviations in 2020.
    Int J Infect Dis. 2026 Sep 15:109119. doi: 10.1016/j.ijid.2026.109119.
    PubMed         Abstract available
    
    

    
    J Infect

15. ORTEGA-FRANCISCO S, Prudente de Aquino MT, Chiuppesi F, Gutierrez-Franco MA Jr, et al
    Phase 2 evaluation of two GEO-CM04S1 dose levels shows comparable safety and broad immunogenicity.
    J Infect. 2026;93:106855.
    PubMed         Abstract available
    
    
16. HARRIS R, Thirard R, Iftikhar H, Middleditch A, et al
    Corrigendum to "Immunogenicity and safety of co-administration of a recombinant shingles vaccine with an mRNA COVID-19 or adjuvanted influenza vaccine: A randomised controlled trial" [J Infect 93 (2026) 106784].
    J Infect. 2026;93:106853.
    PubMed        
    
    
17. BERES SB, Pagnossin D, Olsen RJ, Long SW, et al
    Clinical and population genomic epidemiology of invasive group A streptococcus in Scotland, 2014-2024.
    J Infect. 2026 Sep 18:106860. doi: 10.1016/j.jinf.2026.106860.
    PubMed         Abstract available
    
    

    
    J Med Virol

18. YANG T, Zhang R, Qin S, Zheng Y, et al
    Cross-Neutralization Responses and Persistent Symptoms After SARS-CoV-2 Breakthrough Infections.
    J Med Virol. 2026;98:e71153.
    PubMed         Abstract available
    
    
19. TURANLI EE, Yildirim Arslan S, Dinc F
    Clinical Outcomes in Pediatric COVID-19 Across Two Time Periods: The Role of Coinfection, Age, and Inflammatory Markers.
    J Med Virol. 2026;98:e71156.
    PubMed         Abstract available
    
    

    
    J Virol

20. BUGA CC, Valerio M, Alenquer M, Pires de Miranda M, et al
    Insights into the mechanism of action of the bipartite fusion module of SARS-CoV-2 spike protein.
    J Virol. 2026 Sep 15:e0068826. doi: 10.1128/jvi.00688.
    PubMed         Abstract available
    
    

    
    Nature

21. VARILLY P, Schifferli M, Yang K, Cronan P, et al
    Scalable near-real-time Bayesian phylogenetics for outbreaks with Delphy.
    Nature. 2026 Sep 16. doi: 10.1038/s41586-026-11012.
    PubMed         Abstract available

#Coronavirus Disease Research #References (AMEDEO, September 13 '26)

 

Eur J Radiol

1. GARCIA-HIDALGO C, Naval-Baudin P, Garcia-Garcia JI, Viveros-Castano M, et al
   Dynamic susceptibility contrast perfusion-weighted imaging (DSC-PWI) vascular and metabolic biomarkers for presurgical diagnosis of adult brain tumors across different acquisition parameters.
   Eur J Radiol. 2026;205:113218.
   PubMed         Abstract available
   
   

   
   J Infect

2. QIAN J, Zhang Z, Zhang L
   SARS?CoV?2 spike CTD suppresses host metabolism but restricts viral entry through a PDZ?dependent trade?off.
   J Infect. 2026 Sep 11:106857. doi: 10.1016/j.jinf.2026.106857.
   PubMed        
   
   
3. MAZARAKIS N, Toh ZQ, Neal E, Nguyen C, et al
   Corrigendum to 'Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia' [J Infect 92 (2026)/106727].
   J Infect. 2026;93:106851.
   PubMed        
   
   
4. MAZARAKIS N, Toh ZQ, Neal E, Bright K, et al
   Corrigendum to "The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose" [J Infect 90 (2025)/106447].
   J Infect. 2026;93:106850.
   PubMed        
   
   

   
   J Med Virol

5. TIKHONOVA IV, Dyukina AR, Grinevich AA, Tutukina MN, et al
   Immunological Properties of SARS-CoV-2 S and M Protein Fragments and Their Effects on Respiratory Burst in Human Neutrophils.
   J Med Virol. 2026;98:e71151.
   PubMed         Abstract available
   
   
6. SREELAKSHMI PR, Wagh P, Sarje P, Shinde T, et al
   Distinct Cytokine Signatures and Antibody Neutralization Capacity Differentiate Post-Acute Sequelae of COVID-19 From Recovered Individuals Despite Comparable T Cell Responses.
   J Med Virol. 2026;98:e71145.
   PubMed         Abstract available
   
   

   
   J Travel Med

7. VAN GENDEREN PJJ, van Sprang ENM
   Artificial Intelligence and Complementary Digital Health Technologies Across the Travel Medicine Continuum: A Narrative Review.
   J Travel Med. 2026 Sep 9:taag082. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Virol

8. KIRK J, Sives S, Rayment A, Tappin A, et al
   Spike protein derived from an apathogenic IBV strain confers attenuated phenotype to a nephropathogenic IBV strain.
   J Virol. 2026 Sep 10:e0110326. doi: 10.1128/jvi.01103.
   PubMed         Abstract available
   
   
9. LIU M, Duong MTH, Laocharoensuk T, Aryal B, et al
   Mutations in the macrodomain 1 of nsp3 attenuate PEDV virulence in vivo without impairing in vitro replication.
   J Virol. 2026 Sep 9:e0125126. doi: 10.1128/jvi.01251.
   PubMed         Abstract available
   
   
10. YU R, Zhang L, Zhou P, Zhang Z, et al
    Low-pH-induced conformational changes in the spike protein promote porcine deltacoronavirus infection by enhancing viral binding efficiency to the porcine aminopeptidase receptor.
    J Virol. 2026 Sep 9:e0116826. doi: 10.1128/jvi.01168.
    PubMed         Abstract available
    
    
11. ALVARADO RE, Chen J, Lokugamage KG, Zhou Y, et al
    Antagonism of stress granules is key to SARS-CoV-2 infection and pathogenesis.
    J Virol. 2026 Sep 8:e0099226. doi: 10.1128/jvi.00992.
    PubMed         Abstract available
    
    
12. YAO Z, Zhu Y, Liu N, Hu Y, et al
    The alpha-helix-facilitating amino acid sequence EAAAK dramatically increases the antiviral activity of SARS-CoV-2 fusion-inhibitory peptides via the endosome fusion pathway.
    J Virol. 2026 Sep 8:e0106726. doi: 10.1128/jvi.01067.
    PubMed         Abstract available
    
    

    
    Life Sci

13. HAN D, Beurel E
    The spike protein S1 of SARS-CoV-2 promotes Th17 cell-dependent stress-induced depressive-like behaviors in mice.
    Life Sci. 2026 Sep 8:124672. doi: 10.1016/j.lfs.2026.124672.
    PubMed         Abstract available
    
    

    
    N Engl J Med

14. HAYDEN FG, Sax PE
    Ensitrelvir for Covid-19 Postexposure Prophylaxis. Reply.
    N Engl J Med. 2026;395:1039.
    PubMed        
    
    
15. SUZUKI J, Imai H, Endo S
    Ensitrelvir for Covid-19 Postexposure Prophylaxis.
    N Engl J Med. 2026;395:1039.
    PubMed        
    
    

    
    Travel Med Infect Dis

16. TIMPERLEY EK, Swithenbank L, Beeching NJ, Tang E, et al
    General physicians still fail to take travel histories.
    Travel Med Infect Dis. 2026 Sep 9:103021. doi: 10.1016/j.tmaid.2026.103021.
    PubMed         Abstract available

#Coronavirus Disease Research #References (AMEDEO, Sept. 5 '26)

 

BMJ

1. YANG YT
   Covid-19 vaccine study: scientific asylum should never have been necessary.
   BMJ. 2026;394:e100738.
   PubMed        
   
   

   
   Clin Infect Dis

2. TIPPETT A, Prasad PV, Begier E, Kim SS, et al
   Respiratory Syncytial Virus Hospitalizations in Adults >/=50 Years of Age and Those With Congestive Heart Failure or Chronic Obstructive Pulmonary Disease Exacerbations, 2018-2020.
   Clin Infect Dis. 2026;83:e416-e426.
   PubMed         Abstract available
   
   
3. GODWIN P, Shvachko V, Oppelt T, Wang CY, et al
   Retrospective Cohort Study Assessing Remdesivir Effectiveness in Hospitalized COVID-19 Patients With Renal or Hepatic Comorbidities.
   Clin Infect Dis. 2026 Sep 1:ciag534. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

4. THUNDAKATTIL AV, Prabhu R, Prabhu G, Mani M, et al
   Mixing versus matching booster vaccines: A longitudinal humoral immune kinetics against Omicron in a Malaysian cohort.
   Int J Infect Dis. 2026 Sep 4:109103. doi: 10.1016/j.ijid.2026.109103.
   PubMed         Abstract available
   
   
5. JIN M, Xin H, Zhang J, Huang X, et al
   Epidemiological Characteristics of Scarlet Fever in Liaoning Province, China: A Pre- and Post-Pandemic Comparison, 2005-2024.
   Int J Infect Dis. 2026 Sep 4:109081. doi: 10.1016/j.ijid.2026.109081.
   PubMed         Abstract available
   
   
6. KIM JS, Park JH, Kim J, Lee YC, et al
   Non-invasive aspergillosis following COVID-19 exacerbates the severity of SARS-CoV-2 infection.
   Int J Infect Dis. 2026 Sep 3:109095. doi: 10.1016/j.ijid.2026.109095.
   PubMed         Abstract available
   
   
7. XUE M, Zhou Z, Chao Y, Li J, et al
   Influenza A-Associated Pulmonary Aspergillosis in Critically Ill Patients in the Post-COVID-19 Era: A Multicenter Cohort Study from China.
   Int J Infect Dis. 2026 Aug 29:109089. doi: 10.1016/j.ijid.2026.109089.
   PubMed         Abstract available
   
   

   
   Intensive Care Med

8. MEZA-FUENTES G, Delgado I, Vial PA, Godoy-Faundez A, et al
   Temporal trends in critical care burden and outcomes of Andes virus-associated hantavirus cardiopulmonary syndrome: a national Chilean cohort.
   Intensive Care Med. 2026 Sep 2. doi: 10.1007/s00134-026-08599.
   PubMed         Abstract available
   
   

   
   J Infect

9. LOUBET P, Roubille F, Launay O, Fourati S, et al
   Cardiovascular outcomes and acute human metapneumovirus infection in adults: A systematic literature review.
   J Infect. 2026;93:106843.
   PubMed         Abstract available
   
   
10. WALKER JL, Ribeiro S, Litt D, Patel T, et al
    Antenatal pertussis vaccine effectiveness in England remains high post COVID-19.
    J Infect. 2026;93:106836.
    PubMed         Abstract available
    
    

    
    J Med Virol

11. FERRENA A, Schlamp F, Tuen M, Duerr R, et al
    Durable Interferon-Linked Blood Signatures During COVID-19 Convalescence.
    J Med Virol. 2026;98:e71133.
    PubMed         Abstract available
    
    

    
    J Virol

12. HU L, Tian R, Gao L, Xu N, et al
    PEDV envelope protein promotes viral replication by remodeling host iron homeostasis via the TRIM28-KLF15-FPN axis.
    J Virol. 2026 Sep 2:e0123926. doi: 10.1128/jvi.01239.
    PubMed         Abstract available
    
    
13. DARNLEY JA, Waller SJ, French RK, Parata R, et al
    Divergent coronaviruses discovered in the virome of lamprey with reddening syndrome.
    J Virol. 2026 Sep 2:e0064526. doi: 10.1128/jvi.00645.
    PubMed         Abstract available
    
    

    
    JAMA

14. LIPSON RA, Senerth E, Watson MA, Saini H, et al
    COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season.
    JAMA. 2026 Sep 2. doi: 10.1001/jama.2026.18191.
    PubMed         Abstract available
    
    
15. SENERTH E, Sheikholeslamian SM, Sivakumaran K, Watson MA, et al
    Influenza Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season.
    JAMA. 2026 Sep 2. doi: 10.1001/jama.2026.18126.
    PubMed         Abstract available
    
    
16. ROTEN L, Maurhofer J, Krisai P, Breitenstein A, et al
    Pulmonary Vein Isolation Using Pulsed Field Ablation With vs Without Posterior Wall Isolation in Patients With Symptomatic Persistent Atrial Fibrillation: The PIFPAF-PFA Randomized Clinical Trial.
    JAMA. 2026 Aug 29:e2617598. doi: 10.1001/jama.2026.17598.
    PubMed         Abstract available
    
    

    
    Lancet Infect Dis

17. BADEN LR, Shah NS, Liu STH, Cohen J, et al
    Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet Infect Dis. 2026 Aug 31:S1473-3099(26)00406.
    PubMed         Abstract available
    
    

    
    Nature

18. MAKIN S
    When do infections lead to long COVID? Scientists close in on triggers and treatments for post-viral syndromes.
    Nature. 2026;657:26-28.
    PubMed 

#Coronavirus Disease Research #References (AMEDEO, August 29 '26)

 

Antiviral Res

1. PU F, Guo Y, Pan X, Liu X, et al
   Dual-targeting engineered binding proteins block SARS-CoV-2 infection and complement activation.
   Antiviral Res. 2026;254:106515.
   PubMed         Abstract available
   
   

   
   Clin Infect Dis

2. TRAUTNER BW, Cortes-Penfield NW, Gupta K, Hirsch EB, et al
   Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Selection of Antibiotic Therapy for Complicated UTI.
   Clin Infect Dis. 2025 Dec 19:ciaf460. doi: 10.1093.
   PubMed        
   
   
3. TRAUTNER BW, Cortes-Penfield NW, Gupta K, Hirsch EB, et al
   Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Timing of Intravenous to Oral Antibiotics Transition for Complicated UTI.
   Clin Infect Dis. 2025 Dec 19:ciaf461. doi: 10.1093.
   PubMed        
   
   

   
   Infect Control Hosp Epidemiol

4. PRAKASH-ASRANI R, Shioda K, Bower CW, Steinberg JP, et al
   Impact of hand hygiene on the detection of multidrug-resistant organisms and other pathogens of epidemiologic significance after implementation of an automated hand hygiene monitoring system.
   Infect Control Hosp Epidemiol. 2026 Aug 27:1-7. doi: 10.1017/ice.2026.10524.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

5. WAGATSUMA K, Song Z, Lam TTY, Kwok KO, et al
   Changes in respiratory virus seasonality across the COVID-19 pandemic: a multicentre comparative study in Leicester, Rotterdam, Hong Kong, and Christchurch.
   Int J Infect Dis. 2026 Aug 27:109080. doi: 10.1016/j.ijid.2026.109080.
   PubMed         Abstract available
   
   
6. RAGHUVAMSI PV, Loh SB, Bhattacharya P, Ho J, et al
   Investigating the effectiveness of multimodal data in forecasting SARS-COV-2 case surges.
   Int J Infect Dis. 2026 Aug 25:109062. doi: 10.1016/j.ijid.2026.109062.
   PubMed         Abstract available
   
   

   
   J Infect

7. SANDERSON ND, Dingle KE, Hopkins KMV, Vaughan A, et al
   Clinical validation of an optimised metagenomic nanopore sequencing method for detecting viral respiratory pathogens.
   J Infect. 2026 Aug 22:106839. doi: 10.1016/j.jinf.2026.106839.
   PubMed         Abstract available
   
   

   
   J Med Virol

8. LI J, Song W, Li J, Peng R, et al
   Enhanced Immunogenicity and Cross-Neutralizing Activity of a Trivalent Adenoviral Vector-Based SARS-CoV-2 Vaccine in Mice.
   J Med Virol. 2026;98:e71119.
   PubMed         Abstract available
   
   

   
   J Virol

9. LIU G, Chen J, Wu F, Wei P, et al
   Nanobodies targeting SARS-CoV-2 papain-like protease exert dual antiviral and anti-inflammatory effects.
   J Virol. 2026 Aug 28:e0059926. doi: 10.1128/jvi.00599.
   PubMed         Abstract available
   
   
10. STADLER E, Mordant F, Gartner M, Docken SS, et al
    Reconciliation of titer differences between SARS-CoV-2 neutralizing antibody assays.
    J Virol. 2026 Aug 27:e0082326. doi: 10.1128/jvi.00823.
    PubMed         Abstract available
    
    
11. DE BEIJER NL, Limpens RWAL, Barcena M, Snijder EJ, et al
    Conserved structural features of RNA export pores spanning the double membrane of arterivirus and coronavirus replication organelles.
    J Virol. 2026 Aug 26:e0085926. doi: 10.1128/jvi.00859.
    PubMed         Abstract available
    
    
12. KUMAR S, Lai L, Ellis ML, Patel A, et al
    Immunological imprinting shapes the cross-reactive antibody responses to the KP.2 and LP.8.1 vaccine doses.
    J Virol. 2026 Aug 26:e0074926. doi: 10.1128/jvi.00749.
    PubMed         Abstract available
    
    

    
    JAMA

13. CHUNG TH, Raj SR
    Postural Orthostatic Tachycardia Syndrome (POTS): A Review.
    JAMA. 2026 Aug 24. doi: 10.1001/jama.2026.14809.
    PubMed         Abstract available
    

#Coronavirus Disease Research #References (AMEDEO, August 22 '26)

 

Antiviral Res

1. YURGELONIS I, Rai DK, Lee JT, Li Z, et al
   Antiviral activity of nirmatrelvir against contemporary SARS-CoV-2 variants.
   Antiviral Res. 2026;254:106517.
   PubMed         Abstract available
   
   
2. MALUNE P, Kullik G, Jia X, Bandowski G, et al
   gamma-Monoalkyl triphosphate analogues of acyclic nucleoside phosphonates inhibit SARS-CoV-2 replication in vitro by inducing dissociation of the minimal replication-transcription complex.
   Antiviral Res. 2026;254:106514.
   PubMed         Abstract available
   
   
3. ZOU J, Su L, Lu J, Jing H, et al
   Oligomerized receptor binding domain blocks pan-sarbecovirus infection via enhanced avidity to host receptor.
   Antiviral Res. 2026;254:106516.
   PubMed         Abstract available
   
   

   
   BMJ

4. O'DOWD A
   Covid-19: 40% of affected healthcare workers had long covid, and a quarter still had symptoms after a year.
   BMJ. 2026;394:e100628.
   PubMed        
   
   

   
   Clin Infect Dis

5. RUBIS AB, Youngkin E, Firmender P, Argueta G, et al
   Updated Assessment of the Impact of the Modified Council of State and Territorial Epidemiologists Case Definition for Pertussis on Reported Pertussis.
   Clin Infect Dis. 2026 Aug 22:ciag515. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

6. PINTO TF, Santoro A, de Oliveira ALG, Tavares TS, et al
   Risk of Post-acute Symptoms and Conditions After SARS-CoV-2 Compared to Other Respiratory Viral Infections: A Systematic Review and Meta-Analysis.
   Int J Infect Dis. 2026 Aug 21:109056. doi: 10.1016/j.ijid.2026.109056.
   PubMed         Abstract available
   
   
7. KHAN SMA, Irfan S, Ashraf J, Ghayas H, et al
   Molecularepidemiology and antimicrobial resistance determinants of Corynebacterium diphtheriae causing infections in Karachi, Pakistan, 2023-2024.
   Int J Infect Dis. 2026 Aug 20:109058. doi: 10.1016/j.ijid.2026.109058.
   PubMed         Abstract available
   
   
8. ANZAI A, Nishiura H
   Post-hoc evaluation of travel restrictions during the COVID-19 pandemic in Japan, 2020-2022.
   Int J Infect Dis. 2026 Aug 17:109068. doi: 10.1016/j.ijid.2026.109068.
   PubMed         Abstract available
   
   
9. RAHMOUN MA, Sabate-Elabbadi A, Brun-Buisson C, Watier L, et al
   Impact of the COVID-19 pandemic on the association between sepsis etiology and mortality among ICU patients in France.
   Int J Infect Dis. 2026 Aug 16:109060. doi: 10.1016/j.ijid.2026.109060.
   PubMed         Abstract available
   
   
10. LEAO V, Assad Z, Valtuille Z, Ouldali N, et al
    Shifts in unidentified-pathogen acute hematogenous osteomyelitis incidence after non-pharmaceutical interventions highlight the role of seasonal viruses: an interrupted time-series analysis.
    Int J Infect Dis. 2026 Aug 16:109054. doi: 10.1016/j.ijid.2026.109054.
    PubMed         Abstract available
    
    
11. PENG B, Allen-Benson D, Talebi Y, Ghosh S, et al
    Temporal, Demographic, and Geographic Patterns of Long COVID Incidence in Relation to SARS-CoV-2 Variant Emergence: Insights from the Texas All-Payer Claims Database (TX-APCD).
    Int J Infect Dis. 2026 Aug 16:109051. doi: 10.1016/j.ijid.2026.109051.
    PubMed         Abstract available
    
    
12. AZHAR EI, Alqahtani M, Assiri AM, Al-Abri SS, et al
    MERS-CoV in the Middle East and Africa: from surveillance gaps in humans and dromedary camels to One Health frameworks for spillover, prevention, research and response preparedness.
    Int J Infect Dis. 2026 Aug 15:109046. doi: 10.1016/j.ijid.2026.109046.
    PubMed         Abstract available
    
    

    
    J Med Virol

13. FERRO V, Cozzolino C, Olita C, Severini F, et al
    Viral Landscape, Clinical Impact, and Management Trends in Hospitalized Children for Viral-Associated Lower Respiratory Tract Diseases: A Comparative Analysis of Two Post-Pandemic Seasons in Rome, Italy.
    J Med Virol. 2026;98:e71103.
    PubMed         Abstract available
    
    
14. HUANG Z, Liu W, Zhang N, Guo H, et al
    Respiratory Virus Immunological Dynamics in the Post-Pandemic Era of Southeastern China: A Retrospective Serological Investigation.
    J Med Virol. 2026;98:e71112.
    PubMed         Abstract available
    
    

    
    J Virol

15. ZHANG Y, Fujita S, Kajihara M, Changula K, et al
    Novel African Rhinolophus bat ACE2 sequences reveal the determinants of Afro-Eurasian sarbecovirus entry.
    J Virol. 2026 Aug 21:e0054026. doi: 10.1128/jvi.00540.
    PubMed         Abstract available
    
    
16. ZHENG Y, Luo D, Tian Q, Zhang M, et al
    TPPS4 inhibits PEDV by stabilizing viral RNA G-quadruplex and promoting ER stress: a transfer-learning-driven discovery.
    J Virol. 2026;100:e0077426.
    PubMed         Abstract available
    
    

    
    Lancet Infect Dis

17. BASNYAT B, Adhikari S, Shrestha P, Budhathoki S, et al
    Azithromycin with or without cefixime for suspected or culture-confirmed uncomplicated typhoid fever in Nepal, Bangladesh, and Pakistan (ACT-South Asia): a double-blind, parallel-group, randomised, placebo-controlled, phase 4 trial.
    Lancet Infect Dis. 2026 Aug 20:S1473-3099(26)00358.
    PubMed         Abstract available

#Coronavirus Disease Research #References (AMEDEO, August 16 '26)

 

BMJ

1. LANG K
   What do we know about covid-19 and smell loss?
   BMJ. 2026;394:e100155.
   PubMed        
   
   

   
   Int J Infect Dis

2. SEO G, Joo H, Song K, Kim M, et al
   Corrigendum to "Static and dynamic scoring systems for post-acute sequelae of SARS-CoV-2 in a Korean Cohort" [International Journal of Infectious Diseases Volume 164, 108378, March 2026].
   Int J Infect Dis. 2026;171:108980.
   PubMed        
   
   

   
   Intensive Care Med

3. DAOUD T, Villar J, Annane D
   Corticosteroids in ARDS: old controversies, new insights, and future directions.
   Intensive Care Med. 2026 Aug 13. doi: 10.1007/s00134-026-08567.
   PubMed         Abstract available
   
   

   
   J Infect

4. ZHOU S, Liu C, Liu W, Cai K, et al
   Cross-Neutralizing Antibody Responses to Diverse Coronaviruses in the Human Population.
   J Infect. 2026 Aug 11:106827. doi: 10.1016/j.jinf.2026.106827.
   PubMed         Abstract available
   
   

   
   J Med Virol

5. VIZGIRDA G, Underwood AP, Fahnoe U, Solund C, et al
   SARS-CoV-2 Neutralization Breadth Is Shaped by Variant Exposure and Immune History.
   J Med Virol. 2026;98:e71054.
   PubMed         Abstract available
   
   

   
   Lancet

6. SCHWARTZ CA, Weiss Y
   Hate has no place in medicine.
   Lancet. 2026;408:606.
   PubMed        
   
   

   
   Lancet Infect Dis

7. HE P, Song Y, Guo C, Yu L, et al
   Antibody evasion and receptor binding of SARS-CoV-2 variants PQ.16.1.1 and RK.1.
   Lancet Infect Dis. 2026 Aug 13:S1473-3099(26)00429.
   PubMed        
   

#Coronavirus Disease Research #References (AMEDEO, August 9 '26)

 

BMJ

1. YAMEY G, Titanji BK
   Fauci's Senate hearing riled up the MAGA base-but at the cost of damaging public health.
   BMJ. 2026;394:e100529.
   PubMed        
   
   
2. RUBINSTEIN F, Moraes Morelli D, Palma I, Sanjurjo M, et al
   Evaluation of patient centred digital adherence technology for tuberculosis treatment outcomes: pragmatic randomised controlled trial.
   BMJ. 2026;394:e100195.
   PubMed         Abstract available
   
   

   
   Clin Infect Dis

3. MUNBLIT D, Buonsenso D, Olliaro PL, Semple MG, et al
   Vaccines, Bias, and the Perils of Non-peer-reviewed Studies: Fueling Misinformation and Vaccine Hesitancy.
   Clin Infect Dis. 2026 Aug 5:ciag403. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Infect

4. LI X, Mercade-Besora N, Lam AS, Barboza C, et al
   Effectiveness and waning of the fourth dose mRNA COVID-19 vaccines for the prevention of SARS-CoV2 infection related hospitalisations and deaths.
   J Infect. 2026 Aug 5:106825. doi: 10.1016/j.jinf.2026.106825.
   PubMed         Abstract available
   
   

   
   J Med Virol

5. ACHARYA A, Thurman M, Sutar D, Olasunkanmi OI, et al
   In-Vitro Evaluation of HIV/SARS-CoV-2 Co-Infection Mediated Proteomic Changes in Astrocytes and Pericytes Reveals Altered Signaling Pathways Associated With Neurodegenerative Disorders.
   J Med Virol. 2026;98:e71086.
   PubMed         Abstract available
   
   

   
   J Virol

6. ZHANG L, Chen N, Eichmann A, Nehlmeier I, et al
   The conserved QTQTX motif in the SARS-CoV-2 spike protein is dispensable for cleavage and lung cell entry of the emerging variant BA.3.2.
   J Virol. 2026 Aug 5:e0069126. doi: 10.1128/jvi.00691.
   PubMed         Abstract available
   
   
7. HANRIEDER L, Schreiner S
   One virus-many strategies: type-specific interactions between human adenoviruses and innate immunity.
   J Virol. 2026 Aug 3:e0020426. doi: 10.1128/jvi.00204.
   PubMed         Abstract available
   
   

   
   Life Sci

8. ZANG R, Ren Y, Wang J, Le Z, et al
   SARS-CoV-2 nucleocapsid protein drives pulmonary injury by enhancing GRP75-dependent ER-mitochondria tethering and reprogramming of alveolar macrophages.
   Life Sci. 2026 Aug 8:124625. doi: 10.1016/j.lfs.2026.124625.
   PubMed         Abstract available
   
   

   
   N Engl J Med

9. BUTLER CC, Pinto AD, Little P
   Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients. Reply.
   N Engl J Med. 2026;395:622.
   PubMed        
   
   
10. KUMAR PD
    Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients.
    N Engl J Med. 2026;395:622.
    PubMed        
    
    
11. PUZNIAK L, Hammond J
    Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients.
    N Engl J Med. 2026;395:621.
    PubMed        
    
    

    
    Nat Ment Health

12. ZHOU T, Zhang B, Lu Y, Chen J, et al
    SSRI/SNRI and long COVID in children and adolescents with neuropsychiatric conditions: a cohort study from the RECOVER Initiative.
    Nat Ment Health. 2026;4:1275-1284.
    PubMed         Abstract available
    
    

    
    Nature

13. BUNDELL S, Petric Howe N
    Briefing Chat: Is DNA repair the secret to a long life? Whales and mole rats offer tantalizing hints.
    Nature. 2026 Aug 7. doi: 10.1038/d41586-026-02488.
    PubMed        
    
    
14. KOZLOV M
    COVID can wake up a slew of dormant viruses inside you.
    Nature. 2026 Aug 5. doi: 10.1038/d41586-026-02443.
    PubMed        
    
    
15. MAGUIRE C, Chen J, Rouphael N, Morse BA, et al
    Virus reactivation in acute and long COVID-19.
    Nature. 2026 Aug 5. doi: 10.1038/s41586-026-10740.
    PubMed         Abstract available

#Coronavirus Disease Research #References (AMEDEO, August 1 '26)

 

Antiviral Res

1. WANG K, Gibbons JS, Bisht N, Reyes AC, et al
   SARS-CoV-2 resistance pathways to EDP-235.
   Antiviral Res. 2026;253:106493.
   PubMed         Abstract available
   
   

   
   Emerg Infect Dis

2. KIM S, Chun BC
   Kudoa septempunctata Parasite-Associated Foodborne Disease Outbreaks, South Korea, 2015-2024.
   Emerg Infect Dis. 2026;32:1373-1375.
   PubMed         Abstract available
   
   
3. XU Y, Xiong W, Huang X, Cowling BJ, et al
   Respiratory Syncytial Virus Suppression through Public Health and Social Measures, Hong Kong, China, 2020-2023.
   Emerg Infect Dis. 2026;32:1315-1318.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

4. SPILIOPOULOU A, Betaania L, Giannopoulou I, Leonidou L, et al
   Candidemia in Post-COVID Era: Increasing incidence of endemic fluconazole-resistant Candida parapsilosis and Candidozyma auris.
   Int J Infect Dis. 2026 Jul 30:109018. doi: 10.1016/j.ijid.2026.109018.
   PubMed         Abstract available
   
   
5. GARNERET P, Gaubert G, Nauleau S, Franke F, et al
   Social Deprivation and Remoteness as Determinant of COVID-19 Hospitalisations and Severity: an Area-Level Analysis in South-Eastern France.
   Int J Infect Dis. 2026 Jul 30:109013. doi: 10.1016/j.ijid.2026.109013.
   PubMed         Abstract available
   
   
6. GRIMM K, Hodel EM, Gasser L, Schuller S, et al
   Feasibility of studying respiratory infection transmission in a Swiss household cohort: Findings from the BEready ("Bern, get ready") study.
   Int J Infect Dis. 2026 Jul 29:109019. doi: 10.1016/j.ijid.2026.109019.
   PubMed         Abstract available
   
   
7. RAHAJAMANANA VL, Rabezanahary H, Arroyave A, Wantchecon A, et al
   Dynamics of neutralizing antibodies against enterovirus D68 in adults during the COVID-19 pandemic.
   Int J Infect Dis. 2026 Jul 27:109008. doi: 10.1016/j.ijid.2026.109008.
   PubMed         Abstract available
   
   

   
   J Med Virol

8. MORETTO SL, Cassela PLCS, Trigo GL, Lozovoy MAB, et al
   Investigation of PDCD1 Gene Polymorphisms and Haplotypes in COVID-19 Severity and Outcome in a Brazilian Population.
   J Med Virol. 2026;98:e71090.
   PubMed         Abstract available
   
   
9. PASITTUNGKUL S, Vichaiwattana P, Poovorawan Y, Wanlapakorn N, et al
   Post-Pandemic Resurgence of Respiratory Syncytial Virus in Thailand: Molecular Epidemiology and Sublineage Turnover Among Children, 2023-2025.
   J Med Virol. 2026;98:e71089.
   PubMed         Abstract available
   
   
10. FRASCA F, Maddaloni L, D'Auria A, Fracella M, et al
    SARS-CoV-2 mRNA Vaccination Induces Neutralizing Antibodies and Type I IFN Changes in People Living With HIV.
    J Med Virol. 2026;98:e71067.
    PubMed         Abstract available
    
    
11. HUANG Y, Gao Y, Li Y, Song G, et al
    Application of a Super-Multiplex Microfluidic qPCR System for Detection of Respiratory Pathogens in Patients With Influenza-Like Illness.
    J Med Virol. 2026;98:e71072.
    PubMed         Abstract available
    
    

    
    J Virol

12. XU J, Chan H-w, Yang R, Wu X-R, et al
    Nicotine and cotinine enhance SARS-CoV-2 entry through distinct but complementary mechanisms in human respiratory epithelial cells.
    J Virol. 2026 Jul 31:e0097126. doi: 10.1128/jvi.00971.
    PubMed         Abstract available
    
    
13. LIANG X, Chi X, Deng X
    Coronavirus Nsp15 endoribonuclease: linking viral RNA regulation to immune evasion and viral fitness.
    J Virol. 2026 Jul 31:e0170025. doi: 10.1128/jvi.01700.
    PubMed         Abstract available
    
    
14. ZENG W, Zhang G, Ma H, Xiong L, et al
    ACE2-fused nanobody targeting a cryptic RBD epitope broadly neutralizes SARS-like viruses.
    J Virol. 2026 Jul 30:e0060826. doi: 10.1128/jvi.00608.
    PubMed         Abstract available
    
    
15. HE L, Su Y-WN, Zhang F, Moustafa IM, et al
    Recovery of proofreading-impaired SARS-CoV-2 reveals a mutator phenotype and an ExoN activity threshold for viability.
    J Virol. 2026 Jul 29:e0080926. doi: 10.1128/jvi.00809.
    PubMed         Abstract available
    
    
16. DWIVEDI S, Kar S, Horton AP, Gollihar JD, et al
    ViralMap: predicting features in viral proteins from primary sequence.
    J Virol. 2026 Jul 28:e0075726. doi: 10.1128/jvi.00757.
    PubMed         Abstract available
    
    

    
    Nature

17. CHEN E
    Can long COVID be prevented? Two drugs finally show promise.
    Nature. 2026 Jul 29. doi: 10.1038/d41586-026-02341.
    PubMed        

#SARS-CoV-2 #Surveillance in Free-Ranging #Wildlife in New England and #Virginia, #USA, 2022–2025

 

Abstract

Since its emergence in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected a wide range of animal species, including wildlife. Although SARS-CoV-2 infection has been widely reported in wildlife, particularly in white-tailed deer (WTD; Odocoileus virginianus) across the United States, data on viral circulation in New England wildlife remain limited. Here, we investigated active SARS-CoV-2 infection and serological evidence of previous exposure in free-ranging wildlife from New England and Virginia. We examined samples from 1646 animals representing 29 wildlife species, collected through wildlife rehabilitation centers, clinics, and hunter harvests in New England and Virginia between 2022 and 2025. SARS-CoV-2 RNA was detected in three WTD from Massachusetts and Vermont. Phylogeographic analysis showed that the Vermont WTD SARS-CoV-2 sequences were closely related to contemporaneous human SARS-CoV-2 sequences from the same region, consistent with a possible human-to-deer spillover event. Serological screening by ELISA detected SARS-CoV-2 reactive samples in nine individuals from three species, including Eastern cottontail (Sylvilagus floridanus), Eastern coyote (Canis latrans), and raccoon (Procyon lotor), providing putative evidence of prior SARS-CoV-2 exposure. However, neutralizing antibodies against the SARS-CoV-2 Omicron variant were detected in only a single Eastern cottontail. Overall, these findings indicate sporadic SARS-CoV-2 detection and limited serological evidence of prior exposure among wildlife sampled in New England and Virginia, and highlight the importance of continued surveillance to detect spillover events, monitor viral evolution, and assess the potential risks associated with wildlife reservoirs.

Source: 

Link: https://www.mdpi.com/1999-4915/18/8/832

____